Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 33 | 2024 | 5315 | 2.940 |
Why?
|
Lung Neoplasms | 49 | 2024 | 13382 | 2.800 |
Why?
|
Acrylamides | 15 | 2024 | 260 | 2.500 |
Why?
|
Protein Kinase Inhibitors | 27 | 2024 | 5672 | 2.120 |
Why?
|
Aniline Compounds | 16 | 2024 | 1069 | 1.720 |
Why?
|
Drug Resistance, Neoplasm | 19 | 2024 | 5305 | 1.200 |
Why?
|
Indolizines | 1 | 2023 | 30 | 0.890 |
Why?
|
Mutation | 38 | 2024 | 30054 | 0.870 |
Why?
|
Exons | 7 | 2023 | 2391 | 0.730 |
Why?
|
Small Cell Lung Carcinoma | 4 | 2024 | 423 | 0.670 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2018 | 424 | 0.640 |
Why?
|
Resorcinols | 1 | 2018 | 41 | 0.630 |
Why?
|
Antineoplastic Agents | 13 | 2021 | 13642 | 0.620 |
Why?
|
Mutagenesis, Insertional | 3 | 2021 | 656 | 0.580 |
Why?
|
Isoxazoles | 1 | 2018 | 232 | 0.550 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2018 | 225 | 0.550 |
Why?
|
Molecular Targeted Therapy | 8 | 2023 | 2811 | 0.510 |
Why?
|
Biopsy, Fine-Needle | 1 | 2019 | 1118 | 0.450 |
Why?
|
Pyrimidines | 6 | 2024 | 3028 | 0.390 |
Why?
|
Piperazines | 3 | 2017 | 2523 | 0.330 |
Why?
|
Picornaviridae Infections | 1 | 2009 | 95 | 0.290 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11742 | 0.290 |
Why?
|
Rhinovirus | 1 | 2009 | 203 | 0.290 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2020 | 4026 | 0.290 |
Why?
|
Adenocarcinoma | 4 | 2018 | 6346 | 0.260 |
Why?
|
Respiratory Sounds | 1 | 2009 | 702 | 0.230 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2019 | 738 | 0.220 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3201 | 0.210 |
Why?
|
Humans | 61 | 2024 | 761572 | 0.200 |
Why?
|
Fibroblast Growth Factor 7 | 1 | 2021 | 59 | 0.190 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 243 | 0.190 |
Why?
|
Respiratory Tract Infections | 1 | 2009 | 1010 | 0.180 |
Why?
|
Hepatocyte Growth Factor | 1 | 2021 | 271 | 0.170 |
Why?
|
Diarrhea | 2 | 2023 | 1318 | 0.170 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2021 | 8552 | 0.160 |
Why?
|
Epigenomics | 1 | 2024 | 943 | 0.160 |
Why?
|
Genetic Heterogeneity | 3 | 2020 | 732 | 0.160 |
Why?
|
Disease Progression | 6 | 2021 | 13510 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 257 | 0.150 |
Why?
|
Cell Line, Tumor | 7 | 2019 | 16986 | 0.140 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2019 | 147 | 0.140 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2022 | 1135 | 0.140 |
Why?
|
Immunoconjugates | 1 | 2024 | 953 | 0.140 |
Why?
|
Middle Aged | 23 | 2024 | 220920 | 0.140 |
Why?
|
Indoles | 2 | 2024 | 1833 | 0.140 |
Why?
|
Quinazolinones | 1 | 2018 | 221 | 0.130 |
Why?
|
Eligibility Determination | 1 | 2020 | 421 | 0.130 |
Why?
|
Female | 30 | 2024 | 392686 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 641 | 0.130 |
Why?
|
Maximum Tolerated Dose | 3 | 2024 | 883 | 0.130 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4915 | 0.120 |
Why?
|
Carcinoma, Small Cell | 1 | 2017 | 420 | 0.120 |
Why?
|
Aged, 80 and over | 12 | 2024 | 58986 | 0.120 |
Why?
|
Gene Amplification | 2 | 2016 | 1089 | 0.110 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8002 | 0.110 |
Why?
|
Retreatment | 1 | 2015 | 598 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2019 | 1609 | 0.110 |
Why?
|
Aged | 19 | 2024 | 169310 | 0.110 |
Why?
|
Male | 23 | 2024 | 360842 | 0.110 |
Why?
|
Hemoglobins | 1 | 2019 | 1526 | 0.100 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1342 | 0.100 |
Why?
|
Myenteric Plexus | 1 | 2012 | 49 | 0.100 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2017 | 1626 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1745 | 0.090 |
Why?
|
Prognosis | 4 | 2020 | 29629 | 0.090 |
Why?
|
Translocation, Genetic | 1 | 2016 | 1393 | 0.090 |
Why?
|
Cohort Studies | 5 | 2021 | 41493 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2019 | 3603 | 0.080 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1745 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2019 | 2057 | 0.080 |
Why?
|
Quinazolines | 1 | 2016 | 1371 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2321 | 0.080 |
Why?
|
Mice, Nude | 3 | 2019 | 3614 | 0.080 |
Why?
|
Survival Rate | 2 | 2021 | 12725 | 0.070 |
Why?
|
Adult | 16 | 2024 | 221203 | 0.070 |
Why?
|
Patient Selection | 1 | 2020 | 4244 | 0.070 |
Why?
|
Cell Proliferation | 3 | 2020 | 10448 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10212 | 0.070 |
Why?
|
Treatment Outcome | 7 | 2021 | 64684 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 9177 | 0.070 |
Why?
|
Molecular Epidemiology | 1 | 2009 | 469 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 4575 | 0.070 |
Why?
|
Base Pair Mismatch | 2 | 2003 | 92 | 0.070 |
Why?
|
Gastrointestinal Tract | 1 | 2012 | 833 | 0.070 |
Why?
|
Radiosurgery | 1 | 2015 | 1342 | 0.060 |
Why?
|
Sulfonamides | 3 | 2020 | 1978 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2021 | 571 | 0.060 |
Why?
|
Terminal Care | 1 | 2016 | 1761 | 0.060 |
Why?
|
Benzamides | 2 | 2021 | 1370 | 0.060 |
Why?
|
Alleles | 1 | 2015 | 6864 | 0.060 |
Why?
|
Microsatellite Repeats | 2 | 2003 | 784 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2024 | 80646 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2016 | 12794 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9469 | 0.050 |
Why?
|
Cell Survival | 3 | 2019 | 5791 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 9280 | 0.050 |
Why?
|
Apoptosis | 4 | 2019 | 9489 | 0.050 |
Why?
|
Phylogeny | 1 | 2009 | 2811 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2019 | 6132 | 0.050 |
Why?
|
Sequence Analysis, RNA | 1 | 2009 | 2020 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39107 | 0.040 |
Why?
|
Intestinal Neoplasms | 1 | 2003 | 312 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
Platinum | 1 | 2021 | 220 | 0.040 |
Why?
|
Radiobiology | 1 | 2020 | 90 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2012 | 4415 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2019 | 3430 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 709 | 0.040 |
Why?
|
Triazines | 1 | 2021 | 311 | 0.040 |
Why?
|
Diphenylamine | 1 | 2018 | 49 | 0.040 |
Why?
|
Sequence Deletion | 1 | 2023 | 1494 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2691 | 0.040 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2003 | 592 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 613 | 0.040 |
Why?
|
Lung | 1 | 2017 | 10002 | 0.040 |
Why?
|
Cell Growth Processes | 1 | 2019 | 384 | 0.040 |
Why?
|
Cell Cycle | 2 | 2017 | 2932 | 0.040 |
Why?
|
Keratin-8 | 1 | 2017 | 11 | 0.040 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.040 |
Why?
|
Keratin-18 | 1 | 2017 | 38 | 0.040 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2019 | 242 | 0.040 |
Why?
|
Biopsy | 2 | 2021 | 6766 | 0.040 |
Why?
|
Neoplasm Staging | 2 | 2024 | 11121 | 0.040 |
Why?
|
Prospective Studies | 3 | 2021 | 54426 | 0.040 |
Why?
|
Lactams | 1 | 2017 | 156 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2019 | 385 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2020 | 2264 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2018 | 9031 | 0.030 |
Why?
|
Pyrazoles | 2 | 2017 | 2009 | 0.030 |
Why?
|
Mice | 5 | 2024 | 81533 | 0.030 |
Why?
|
Lactams, Macrocyclic | 1 | 2017 | 318 | 0.030 |
Why?
|
North America | 1 | 2018 | 1276 | 0.030 |
Why?
|
Pyridines | 2 | 2017 | 2875 | 0.030 |
Why?
|
Animals | 7 | 2024 | 168467 | 0.030 |
Why?
|
Imidazoles | 1 | 2021 | 1180 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2024 | 2827 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10766 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 899 | 0.030 |
Why?
|
Time Factors | 3 | 2021 | 39970 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 809 | 0.030 |
Why?
|
Aminopyridines | 1 | 2017 | 573 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 1962 | 0.030 |
Why?
|
Gene Expression | 2 | 2017 | 7581 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 917 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2468 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2626 | 0.030 |
Why?
|
Codon | 1 | 2015 | 601 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1334 | 0.030 |
Why?
|
Tumor Burden | 1 | 2018 | 1893 | 0.030 |
Why?
|
Up-Regulation | 1 | 2021 | 4124 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3514 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 934 | 0.020 |
Why?
|
Gene Dosage | 1 | 2016 | 1218 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2019 | 2141 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2019 | 2385 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3801 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2015 | 1739 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1092 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4399 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6484 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5247 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2161 | 0.020 |
Why?
|
DNA Damage | 1 | 2019 | 2449 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1899 | 0.020 |
Why?
|
Patient Care Team | 1 | 2020 | 2521 | 0.020 |
Why?
|
Mushroom Poisoning | 1 | 1968 | 5 | 0.020 |
Why?
|
Immunohistochemistry | 3 | 2012 | 11076 | 0.020 |
Why?
|
Hospitalization | 1 | 2009 | 10721 | 0.020 |
Why?
|
Neoplasms | 1 | 2017 | 22173 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2018 | 18253 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3877 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3575 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5035 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2917 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4111 | 0.020 |
Why?
|
Infant | 1 | 2009 | 36192 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2015 | 1376 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5790 | 0.020 |
Why?
|
Signal Transduction | 2 | 2021 | 23447 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4652 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6815 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 6180 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 59255 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14416 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2003 | 6935 | 0.010 |
Why?
|
MutS Homolog 2 Protein | 1 | 2003 | 197 | 0.010 |
Why?
|
Adolescent | 3 | 2021 | 88324 | 0.010 |
Why?
|
Swine | 1 | 2012 | 5915 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6485 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 12990 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16592 | 0.010 |
Why?
|
Neoplasm Proteins | 2 | 2003 | 3617 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17904 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2003 | 1989 | 0.010 |
Why?
|
Rats | 1 | 2012 | 23741 | 0.010 |
Why?
|
Age of Onset | 1 | 2003 | 3306 | 0.010 |
Why?
|
Quality of Life | 1 | 2016 | 13367 | 0.010 |
Why?
|
DNA Repair | 1 | 2003 | 2046 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20571 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2003 | 2898 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2003 | 4513 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2003 | 4937 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2003 | 5799 | 0.000 |
Why?
|
Age Factors | 1 | 2003 | 18398 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 9610 | 0.000 |
Why?
|